 |
Quick Links |
| Information by Disease |
|
|
|
| Cancer News |
|
|
|
| Conference Coverage |
|
|
|
| AZN | $44.82 | -0.37 (-0.82%)
| | NVS | $53.13 | -0.16 (-0.3%)
| | SNY | $37.67 | -0.01 (-0.03%)
| | GSK | $41.53 | 0.06 (0.14%)
|
|
|
Head and Neck Cancer
| 572016 |
ErbB-2 and EGFR dual kinase inhibitor |
GlaxoSmithKline |
III |
| Advexin (adenoviral p53) |
Gene therapy |
Introgen Therapeutics, Interferon Sciences |
III |
| CI-1033 |
Erb-b2 and EGFR dual kinase inhibitor |
Pfizer |
II |
| HuMax-EGFr |
Hoffman LaRoche |
I/II |
|
| Erbitux (cetuximab) |
Anti-EGFR monoclonal antibody |
ImClone Systems and Bristol-Myers Squibb |
III |
| INGN 201 |
Gene therapy |
Introgen Therapeutics |
III |
| Iressa (gefitinib) |
EGFR tyrosine kinase inhibitor |
AstraZeneca |
III |
| Medpulser Bleomycin |
Electroporation therapy system (EPT) |
Genetronics |
III |
| MG98 |
Antisense |
MethylGene and MGI Pharma |
II |
| Multikine |
Interleukin-2 |
Cel-Sci |
II |
| ONYX-015 |
Gene therapy |
Onyx Pharmaceuticals |
II |
| SAHA |
Histone deacetylase inhibitor |
Aton Pharma |
II |
| Sarasar (lonafarnib) |
Oral Farnesyl Protein Transferase Inhibitor |
Schering-Plough |
II |
| Tarceva (erlotinib) |
EGFR inhibitor |
Genetech OSI |
II |
| Taxotere (docetaxel) |
Taxoid |
Aventis |
III |
| TGDCC-E1A |
Gene therapy |
Targeted Genetics |
II |
| Tirapazamine |
Bioreductive agent |
Sanofi-Synthelabo |
III |
| Triapine |
Antineoplastic |
Vion Lilly |
II |
|
For more information contact us at clinicaltrials@cancerconsultants.com
 |
 View Drugs in Pipeline By Disease |
 |
|
|
|
 |
|
 |
|
|
Patient Home
Meeting Calendar
